Abstract
Cytotoxic T lymphocyte-associated antigen-4 (CTLA4) A49G is a polymorphism that is extensively studied in various cancers. To investigate whether it is associated with the occurrence of glioma in Chinese patients, we performed a case–control research study with 670 patients and 680 controls. In this group, we found that the genotype at this locus is significantly associated with glioma risk (GG vs. AA: P = 0.045; GG + AG vs. AA: P = 0.013). In some subgroups, G allele carriers are significantly less represented. We also observed significant correlations between the polymorphism genotype and glioma risk in patients with WHO histologic stages. We conclude that CTLA4 A49G might be a potential clinical biomarker for distinguishing persons with a high risk for developing gliomas.
Similar content being viewed by others
References
Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1(3):220–228
Aloisi F, Ria F, Penna G, Adorini L (1998) Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 160(10):4671–4680
Carson MJ, Sutcliffe JG, Campbell IL (1999) Microglia stimulate naive t-cell differentiation without stimulating T-cell proliferation. J Neurosci Res 55(1):127–134
Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3(7):611–618
Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165(2):114–120
Flynn S, Stockinger B (2003) Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood 101(11):4472–4478
Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Dehaghani AS (2004) Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 86(1):1–7
Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10(A):133–146
Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A (2007) CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 22(12):2283–2287
Hunt KA, McGovern DP, Kumar PJ, Ghosh S, Travis SP, Walters JR, Jewell DP, Playford RJ, van Heel DA (2005) A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet 13(4):440–444
Hutchcroft JE, Bierer BE (1996) Signaling through CD28/CTLA-4 family receptors—puzzling participation of phosphatidylinositol-3 kinase. J Immunol 156(11):4071–4074
Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJ, Adema GJ (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 11(4):394–402
Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3:255–268
Kouki T, Sawai P, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of graves’ disease. J Immunol 165(11):6606–6611
Kulprathipanja NV, Kruse CA (2004) Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells. J Neuroimmunol 153(1–2):76–82
Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2(3):145–152
Liu Y, Zhang H, Zhou K, Chen L, Xu Z, Zhong Y, Liu H, Li R, Shugart YY, Wei Q, Jin L, Huang F, Lu D, Zhou L (2007) Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. Carcinogenesis 28(9):1906–1913
Maeurer M, Loserth S, Kolb-Maeurer A, Ponath A, Wiese S, Kruse N, Rieckmann P (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54(1):1–8
Merchant TE, Pollack IF, Loeffler JS (2010) Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 20(1):58–66
Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, Noli A, Gabbas A (2004) Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-hodgkin’s lymphoma. Am J Hematol 76(1):14–18
Raffel C (1996) Molecular biology of pediatric gliomas. J Neurooncol 28(2–3):121–128
Rudd CE, Schneider H (2003) Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 3(7):544–556
Schartner JM, Hagar AR, Van Handel M, Zhang LY, Nadkarni N, Badie B (2005) Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51(4):279–285
Sehgal A, Berger MS (2007) Basic concepts of immunology and neuroimmunology. Neurosurg Focus 9(6):e1
Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2(2):116–126
Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, Lin M, Wang PT, Huang WC, Chen TC, Yang YC (2007) CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 28(6):1237–1240
Sun T, Zhou YF, Yang M, Hu ZB, Tan W, Han XH, Shi YK, Yao JR, Guo YL, Yu DK, Tian T, Zhou XY, Shen HB, Lin DX (2008) Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 68(17):7025–7034
Tatter SB, Wilson CB, IV HarshGR (1995) Neuroepithelial tumors of the adult brain. In: Youmans JR (ed) Neurological surgery, 4th edn., vol. 4: Tumors. W. B. Saunders Co, Philadelphia, pp 2612–2684
Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KMD, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RCJ, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SCL (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(6939):506–511
Wang LH, Li DL, Fu ZK, Li H, Jiang W, Li DJ (2007) Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 7:173
Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, Nelson HH (2009) CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res 69(15):6158–6163
Wong YK, Chang KW, Cheng CY, Liu CJ (2006) Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 35(1):51–54
Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ (2009) A novel functional polymorphism, 16974 A/C, in the interleukin-12–3’ untranslated region is associated with risk of glioma. DNA Cell Biol 28(7):335–341
Zheng CY, Huang DR, Liu L, Bjorkholm M, Holm G, Yi Q, Sundblad A (2001) Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol 112(1):216–218
Acknowledgments
This work was supported by China National Key Basic Research Program Grants (2002CB512902), National 211 Environmental Genomics Grant. We thank all the patients and individuals for their participation, the clinicians and other hospital staff, cancer registries, and study staff.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Qihan Wu, Xiaoying Zhan, and Tonghai Dou contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wu, Q., Zhan, X., Dou, T. et al. CTLA4 A49G Polymorphism Shows Significant Association With Glioma Risk in a Chinese Population. Biochem Genet 49, 190–201 (2011). https://doi.org/10.1007/s10528-010-9398-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-010-9398-0